Literature DB >> 29444362

The use of JAK inhibitors in the treatment of progressive systemic sclerosis.

S C Deverapalli1, D Rosmarin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29444362     DOI： 10.1111/jdv.14876

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  6 in total

Review 1.  Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review.

Authors:  Avgoustina Kyriakou; Konstantinos Parperis; Elena Nikiphorou; Savvas Psarelis
Journal:  Rheumatol Int       Date:  2021-01-12       Impact factor: 2.631

Review 2.  Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.

Authors:  Alain Lescoat; David Roofeh; Masataka Kuwana; Robert Lafyatis; Yannick Allanore; Dinesh Khanna
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-01       Impact factor: 10.817

Review 3.  Emerging Topical and Systemic JAK Inhibitors in Dermatology.

Authors:  Farzan Solimani; Katharina Meier; Kamran Ghoreschi
Journal:  Front Immunol       Date:  2019-12-03       Impact factor: 7.561

Review 4.  Esophageal Dysfunction in Systemic Sclerosis: An Update.

Authors:  Bo Li; Junqing Yan; Jincheng Pu; Jianping Tang; Shuchang Xu; Xuan Wang
Journal:  Rheumatol Ther       Date:  2021-10-09

5.  JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis.

Authors:  Zhanying Hou; Xuehan Su; Guangming Han; Ruzeng Xue; Yangxia Chen; Ye Chen; Huan Wang; Bin Yang; Yunsheng Liang; Suyun Ji
Journal:  Front Med (Lausanne)       Date:  2022-06-06

Review 6.  Upcoming treatments for morphea.

Authors:  Dan Wenzel; Nazgol-Sadat Haddadi; Khashayar Afshari; Jillian M Richmond; Mehdi Rashighi
Journal:  Immun Inflamm Dis       Date:  2021-07-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.